121 related articles for article (PubMed ID: 38430032)
1. Synergistic anti-tumor effects of lenalidomide and gefitinib by upregulating ADRB2 and inactivating the mTOR/PI3K/AKT signaling pathway in lung adenocarcinoma.
Zhou S; Deng M; Bian X; Shi J; Liang R; Tao M
Cell Mol Biol (Noisy-le-grand); 2024 Feb; 70(2):120-127. PubMed ID: 38430032
[TBL] [Abstract][Full Text] [Related]
2. Reciprocal positive regulation between Cx26 and PI3K/Akt pathway confers acquired gefitinib resistance in NSCLC cells via GJIC-independent induction of EMT.
Yang J; Qin G; Luo M; Chen J; Zhang Q; Li L; Pan L; Qin S
Cell Death Dis; 2015 Jul; 6(7):e1829. PubMed ID: 26203858
[TBL] [Abstract][Full Text] [Related]
3. Polyphyllin II Restores Sensitization of the Resistance of PC-9/ZD Cells to Gefitinib by a Negative Regulation of the PI3K/Akt/mTOR Signaling Pathway.
Zheng R; Jiang H; Li J; Liu X; Xu H
Curr Cancer Drug Targets; 2017; 17(4):376-385. PubMed ID: 28093061
[TBL] [Abstract][Full Text] [Related]
4. [STE029 Overcomes EGFR-TKI Resistance in Human Lung Adenocarcinoma].
Huang L; Hou M; Liu J; Li Y; Shen W; Zhou Q
Zhongguo Fei Ai Za Zhi; 2022 Nov; 25(11):771-781. PubMed ID: 36419390
[TBL] [Abstract][Full Text] [Related]
5. MiR-133a-3p attenuates resistance of non-small cell lung cancer cells to gefitinib by targeting SPAG5.
Li Q; Wang Y; He J
J Clin Lab Anal; 2021 Jul; 35(7):e23853. PubMed ID: 34057242
[TBL] [Abstract][Full Text] [Related]
6. Akt kinase LANCL2 functions as a key driver in EGFR-mutant lung adenocarcinoma tumorigenesis.
Lou Y; Xu J; Zhang Y; Zhang W; Zhang X; Gu P; Zhong H; Wang H; Lu J; Han B
Cell Death Dis; 2021 Feb; 12(2):170. PubMed ID: 33568630
[TBL] [Abstract][Full Text] [Related]
7. FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer.
Sun C; Gao W; Liu J; Cheng H; Hao J
Respir Res; 2020 Aug; 21(1):210. PubMed ID: 32778129
[TBL] [Abstract][Full Text] [Related]
8. PLAUR Confers Resistance to Gefitinib Through EGFR/P-AKT/Survivin Signaling Pathway.
Zhou J; Kwak KJ; Wu Z; Yang D; Li J; Chang M; Song Y; Zeng H; Lee LJ; Hu J; Bai C
Cell Physiol Biochem; 2018; 47(5):1909-1924. PubMed ID: 29961070
[TBL] [Abstract][Full Text] [Related]
9. The Underlying Mechanism Involved in Gefitinib Resistance and Corresponding Experiment Validation in Lung Cancer.
Song P; Zhou J; Wu K; Wang W; Gu S
Mediators Inflamm; 2023; 2023():9658912. PubMed ID: 37205010
[TBL] [Abstract][Full Text] [Related]
10. BYL719 reverses gefitinib-resistance induced by PI3K/AKT activation in non-small cell lung cancer cells.
Yu Y; Xiao Z; Lei C; Ma C; Ding L; Tang Q; He Y; Chen Y; Chang X; Zhu Y; Zhang H
BMC Cancer; 2023 Aug; 23(1):732. PubMed ID: 37553597
[TBL] [Abstract][Full Text] [Related]
11. Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells.
Chen J; Bi H; Hou J; Zhang X; Zhang C; Yue L; Wen X; Liu D; Shi H; Yuan J; Liu J; Liu B
Cell Death Dis; 2013 Sep; 4(9):e814. PubMed ID: 24071646
[TBL] [Abstract][Full Text] [Related]
12. Shenqi Fuzheng injection restores the sensitivity to gefitinib in non-small cell lung cancer by inhibiting the IL-22/STAT3/AKT pathway.
Wang J; He X; Jia Z; Yan A; Xiao K; Liu S; Hou M; Long Y; Ding X
Pharm Biol; 2024 Dec; 62(1):33-41. PubMed ID: 38100532
[TBL] [Abstract][Full Text] [Related]
13. MiR-128 reverses the gefitinib resistance of the lung cancer stem cells by inhibiting the c-met/PI3K/AKT pathway.
Jiang J; Feng X; Zhou W; Wu Y; Yang Y
Oncotarget; 2016 Nov; 7(45):73188-73199. PubMed ID: 27690301
[TBL] [Abstract][Full Text] [Related]
14. Relationship between long non-coding RNA PCAT-1 expression and gefitinib resistance in non-small-cell lung cancer cells.
Wang S; Liu C; Lei Q; Wu Z; Miao X; Zhu D; Yang X; Li N; Tang M; Chen Y; Wang W
Respir Res; 2021 May; 22(1):146. PubMed ID: 33980216
[TBL] [Abstract][Full Text] [Related]
15. Synaptotagmin 12 (SYT12) Gene Expression Promotes Cell Proliferation and Progression of Lung Adenocarcinoma and Involves the Phosphoinositide 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Pathway.
Liu K; Luo J; Shao C; Ren Z; Sun S; Zhu Y; Zhou H; Jiang Z; Li X; Gu W; Xu Y; Qiang Y; Ren B; Xu L; Wu H; Shen Y
Med Sci Monit; 2020 Feb; 26():e920351. PubMed ID: 32108133
[TBL] [Abstract][Full Text] [Related]
16. Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.
Li H; Schmid-Bindert G; Wang D; Zhao Y; Yang X; Su B; Zhou C
Adv Med Sci; 2011; 56(2):275-84. PubMed ID: 22037177
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of gefitinib-induced growth inhibition by Marsdenia tenacissima extract in non-small cell lung cancer cells expressing wild or mutant EGFR.
Han SY; Ding HR; Zhao W; Teng F; Li PP
BMC Complement Altern Med; 2014 May; 14():165. PubMed ID: 24884778
[TBL] [Abstract][Full Text] [Related]
18. FZKA reverses gefitinib resistance by regulating EZH2/Snail/EGFR signaling pathway in lung adenocarcinoma.
Tang Q; Xu M; Long S; Yu Y; Ma C; Wang R; Li J; Wang X; Fang F; Han L; Wu W; Wang S
J Ethnopharmacol; 2024 Jan; 318(Pt A):116646. PubMed ID: 37269912
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.
Qu Y; Wu X; Yin Y; Yang Y; Ma D; Li H
J Exp Clin Cancer Res; 2014 Jun; 33(1):52. PubMed ID: 24939055
[TBL] [Abstract][Full Text] [Related]
20. Exosomes transmit T790M mutation-induced resistance in EGFR-mutant NSCLC by activating PI3K/AKT signalling pathway.
Liu X; Jiang T; Li X; Zhao C; Li J; Zhou F; Zhang L; Zhao S; Jia Y; Shi J; Gao G; Li W; Zhao J; Chen X; Su C; Ren S; Zhou C
J Cell Mol Med; 2020 Jan; 24(2):1529-1540. PubMed ID: 31894895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
